Targeting Cyclin-Dependent Kinases with Small Molecule Inhibitors
Authors:
- 19 August 2009
- book chapter
- Published by Springer Nature
- p. 235-244
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- A phase I dose-escalation study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the novel cyclin-dependent kinase inhibitor SCH 727965 administered every 3 weeks in subjects with advanced malignanciesJournal of Clinical Oncology, 2008
- CDK inhibitors in cancer therapy: what is next?Trends in Pharmacological Sciences, 2008
- Cdk1 is sufficient to drive the mammalian cell cycleNature, 2007
- Mice thrive without Cdk4 and Cdk2Molecular Oncology, 2007
- Synthesis of PHA‐690509 labelled with 14CJournal of Labelled Compounds and Radiopharmaceuticals, 2007
- In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trialsMolecular Cancer Therapeutics, 2006
- Is Cyclin D1-CDK4 kinase a bona fide cancer target?Cancer Cell, 2006
- Pyrido[2,3-d]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4Journal of Medicinal Chemistry, 2005
- ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agentCancer Cell, 2005
- Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in miceNature Genetics, 2003